Twinning participaties has invested in Curix to further develop our technology. Twinning is an investor who focusses on not only creating financial return, but also social return. Peter Frinking, managing director Curix adds: With Twinning's investment, we are working towards the first clinical evaluations. Twinning is not just an anonymous financier, but is genuinely involved and interested. Twinning published an article about our partnership.

As part of the ambitious European research initiative UNLOOC (Unlocking the data content of Organ-on-Chips), Curix is pioneering new methods for drug delivery to the brain, aiming to transform treatment approaches for neurological diseases such as Alzheimer’s and brain tumors.